Effect of Head and Gaze Position on Soft Toric Contact Lens Performance

Primary Hypotheses:

Senofilcon A will provide significantly less rotation with subjects in a recumbent position than Filcon II 3 monthly .

Etafilcon A will provide significantly less rotation with subjects in a recumbent position than Filcon II 3 1 1 day .

Etafilcon A will provide rotation with subjects a recumbent position non-inferior to nelfilcon A. A margin of 5 degrees will be used.

Secondary Hypotheses:

Senofilcon A will have significantly better monocular visual performance with subjects in a recumbent position than Filcon II 3 monthly.

Etafilcon A for astigmatism will have significantly better monocular visual performance with subjects in a recumbent position than Filcon II 3 1 day.

Etafilcon A will have monocular visual performance with subjects in a recumbent position non-inferior nelfilcon A. A margin of 0.05 LogMAR will be used.

Study Overview

• Status: Completed
• Conditions: Astigmatism; Myopia
• Intervention / Treatment: Device: senofilcon A; Device: etafilcon A; Device: nelfilcon A; Device: Filcon II 3; Device: Filcon II 3

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United Kingdom
  • Surrey
    • Farnham, Surrey, United Kingdom, GU97EN

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 53 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age range 18-60 years.
• Read, understand, and sign written Statement of Informed Consent.
• Appear able and willing to adhere to the instructions set forth in the clinical protocol.
• Be existing soft contact lens wearers (no extended wear in the last 3 months, but silicone hydrogels in daily wear are allowed).
• Require a visual correction in both eyes (monovision allowed but no monofit).
• Have a spherical contact lens requirement in the range -1.00 to -6.00D.
• Have astigmatism of between -0.75 and -2.00DC in both eyes.
• Have axes of astigmatism within +/-10° of the following available lens axes: 70°, 90°, 110°, 20°, 180° & 160°, i.e. 60-120, 10-30 and 150-180.
• Monocular distance visual acuity correctable to 6/9 or better in each eye with best sphero-cylindrical refraction.

• Have normal eyes with no evidence of any ocular abnormality or disease. For the purposes of this study a normal eye is defined as one having:

  i) Clear cornea ii) No anterior segment disorder iii) No clinically significant slit lamp findings (i.e. edema, staining, scarring, vascularization, infiltrates or abnormal opacities) iv) No other active ocular disease or recent surgery

Exclusion Criteria:

• Having worn rigid gas permeable (RGP) contact lenses within the last 30 days or polymethyl methacrylate (PMMA) contact lenses within the last 3 months.
• Clinically significant corneal edema, corneal vascularization, corneal staining, tarsal abnormalities, bulbar injection or any other abnormality of the cornea that would contraindicate contact lens wear.
• Extended lens wear in last 3 months.
• Any systemic or topical medications that will in the investigator's opinion affect ocular physiology or contact lens performance.
• Any systemic disease affecting ocular health.
• Abnormal lacrimal secretions.
• Keratoconus or other corneal irregularity.
• Pregnancy, lactating or planning a pregnancy at the time of enrolment.
• Participation in any concurrent clinical trial.
• Any previous anterior ocular surgery.
• Subjects who are known to have an infectious systemic disease (e.g.,hepatitis, tuberculosis).
• Subjects who are known to have an immunosuppressive disease (e.g., HIV positive).
• Subjects who are known to have diabetes.
• Employees or family members of the Research site, Principal Investigator or study team.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Single

Number of Arms

12

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Sequence 1; Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows: Filcon II 3, nelfilcon A, etafilcon A, senofilcon A, Filcon II 3	Device: senofilcon A; bilateral daily use soft contact lens; Device: etafilcon A; bilateral daily use soft contact lens; Device: nelfilcon A; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lenses
Experimental: Sequence 2; Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows: Filcon II 3, nelfilcon A, etafilcon A, Filcon II 3, senofilcon A	Device: senofilcon A; bilateral daily use soft contact lens; Device: etafilcon A; bilateral daily use soft contact lens; Device: nelfilcon A; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lenses
Experimental: Sequence 3; Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows: Filcon II 3, etafilcon A, nelfilcon A, senofilcon A, Filcon II 3	Device: senofilcon A; bilateral daily use soft contact lens; Device: etafilcon A; bilateral daily use soft contact lens; Device: nelfilcon A; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lenses
Experimental: Sequence 4; Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows: Filcon II 3, etafilcon A, nelfilcon A, Filcon II 3, senofilcon A	Device: senofilcon A; bilateral daily use soft contact lens; Device: etafilcon A; bilateral daily use soft contact lens; Device: nelfilcon A; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lenses
Experimental: Sequence 5; Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows: nelfilcon A, Filcon II 3, etafilcon A, senofilcon A, Filcon II 3	Device: senofilcon A; bilateral daily use soft contact lens; Device: etafilcon A; bilateral daily use soft contact lens; Device: nelfilcon A; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lenses
Experimental: Sequence 6; Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows: nelfilcon A, Filcon II 3, etafilcon A, Filcon II 3, senofilcon A	Device: senofilcon A; bilateral daily use soft contact lens; Device: etafilcon A; bilateral daily use soft contact lens; Device: nelfilcon A; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lenses
Experimental: Sequence 7; Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows: nelfilcon A, etafilcon A, Filcon II 3, senofilcon A, Filcon II 3	Device: senofilcon A; bilateral daily use soft contact lens; Device: etafilcon A; bilateral daily use soft contact lens; Device: nelfilcon A; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lenses
Experimental: Sequence 8; Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows: nelfilcon A, etafilcon A, Filcon II 3, Filcon II 3, senofilcon A	Device: senofilcon A; bilateral daily use soft contact lens; Device: etafilcon A; bilateral daily use soft contact lens; Device: nelfilcon A; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lenses
Experimental: Sequence 9; Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows: etafilcon A, Filcon II 3, nelfilcon A, senofilcon A, Filcon II 3	Device: senofilcon A; bilateral daily use soft contact lens; Device: etafilcon A; bilateral daily use soft contact lens; Device: nelfilcon A; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lenses
Experimental: Sequence 10; Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows: etafilcon A, Filcon II 3, nelfilcon A, Filcon II 3, senofilcon A	Device: senofilcon A; bilateral daily use soft contact lens; Device: etafilcon A; bilateral daily use soft contact lens; Device: nelfilcon A; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lenses
Experimental: Sequence 11; Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows: etafilcon A, nelfilcon A, Filcon II 3, senofilcon A, Filcon II 3	Device: senofilcon A; bilateral daily use soft contact lens; Device: etafilcon A; bilateral daily use soft contact lens; Device: nelfilcon A; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lenses
Experimental: Sequence 12; Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows: etafilcon A, nelfilcon A, Filcon II 3, Filcon II 3, senofilcon A	Device: senofilcon A; bilateral daily use soft contact lens; Device: etafilcon A; bilateral daily use soft contact lens; Device: nelfilcon A; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lens; Device: Filcon II 3; bilateral daily use soft contact lenses

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Lens Orientation in Recumbent Position	rotation from zero position also described as absolute value of the rotation.	up to 60 minutes in recumbent position

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Monocular Visual Acuity in Recumbent Position	Visual Acuity measured in LogMAR units. High contrast visual acuity (VA) was measured in both eyes using a 3m LogMAR test chart at 2.5m testing distance (subsequently converted).	up to 60 minutes in recumbent position

Collaborators and Investigators

• Sponsor: Johnson & Johnson Vision Care, Inc.

Study record dates

Study Major Dates

• Study Start: August 1, 2012
• Primary Completion (Actual): March 1, 2013
• Study Completion (Actual): March 1, 2013

Study Registration Dates

• First Submitted: April 13, 2012
• First Submitted That Met QC Criteria: April 13, 2012
• First Posted (Estimate): April 17, 2012

Study Record Updates

• Last Update Posted (Actual): June 19, 2018
• Last Update Submitted That Met QC Criteria: June 18, 2018
• Last Verified: May 1, 2015

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Refractive Errors; Astigmatism
• Other Study ID Numbers: CR-005141